Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Phase 1 Open-label Study of 123I-ATT001 in Subjects with Relapsed Glioblastoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2024
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics Ltd
Details : The acquisition provides Ariceum with an expanded portfolio of therapeutic and diagnostic assets including, AT-001, a I-123-labelled PARP inhibitor for the treatment of aggressively growing cancers and it has UK ILAP approval for primary and recurrent gl...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : $2.5 million
January 06, 2023
Lead Product(s) : ATD-001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ariceum Therapeutics
Deal Size : $44.0 million
Deal Type : Acquisition
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
August 06, 2018
Reset All
